

ContraPest® Approved for General Use in New York State

PHOENIX, Feb. 6, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced that the New York State Department of Environmental Conservation has approved ContraPest for General Use, removing "Restricted Use Pesticide" (RUP) from the label of ContraPest. This expands the market for ContraPest dramatically in New York, as it no longer requires application by specially licensed pest control companies and eliminates restrictive handling and paperwork.

In 2018, the EPA removed the RUP label and approved ContraPest for General Use. However, individual states maintain their own requirements for General Use classification. New York now becomes the 49th state to remove the RUP label from ContraPest and joins Washington D.C. and major U.S. Territories using ContraPest under the General Use label, validating years of effective and incident-free experience.

SENESTECH

"The removal of the RUP label in New York now allows us to significantly expand our efforts to introduce ContraPest in New York," said Joel Fruendt, SenesTech's CEO. "The Mayor of New York City has declared fighting rats as a top priority. As we have shown in other markets, adding ContraPest to New York's pest control toolbox can show dramatic reduction in rats, proving population control is the key to success in the ongoing battle. We look forward to working with government agencies, agribusiness, food production facilities, property managers and other non-PMPs, including do-it-yourselfers, who want to effectively control their rat populations with ContraPest."

About SenesTech

We are the experts in rat fertility control. Our passion is to create a healthy environment by better controlling rat pest populations. We keep an inescapable truth in mind. Two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year. We invented ContraPest, the only U.S. EPA registered contraceptive for male and female rats. ContraPest fits seamlessly into all integrated pest management programs, greatly improving the overall goal of effective rat management. We strive for clean cities, efficient businesses, and happy households – with a product that was designed to be effective and sustainable without killing rats. At SenesTech, we are committed to improving the health of the world by humanely managing animal populations through fertility control.

For more information visit <https://senestech.com/> and <https://contrapestore.com>.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, among others, our belief that removing RUP from the label of ContraPest in the state of New York expands the market for ContraPest dramatically in New York; our belief that the removal of the RUP label validates years of effective and incident-free experience; our belief that the removal of the RUP label in New York now allows us to significantly expand our efforts to introduce ContraPest in New York; our belief that adding ContraPest to New York's pest control toolbox can show dramatic reduction in rats, proving population control is the key to success in the ongoing battle; and our belief that ContraPest fits seamlessly into all integrated pest management programs, greatly improving the overall goal of effective rat management. Forward-looking statements may describe future expectations, plans, results or strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases. You are

cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the impacts and implications of the COVID-19 pandemic, the successful commercialization of our products, market acceptance of our products, regulatory approval and regulation of our products and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACT:

Investors: Robert Blum, Lytham Partners, LLC, 602-889-9700, senestech@lythampartners.com

Press: Nicole Williams, Chief Revenue Officer, SenesTech, Inc., 928-779-4143

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143

SOURCE SenesTech, Inc.

<https://senestech.investorroom.com/2023-02-06-ContraPest-R-Approved-for-General-Use-in-New-York-State>